Showing results (111-120 of 131) with videos related to
Sort By:
Pageof 14
Cancer Medicine|December 22, 2016
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survivalJorge D Ramos, Martin F Casey, Simon J Crabb, et al.British Journal of Haematology|August 9, 2019
Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016Vania Tietsche de Moraes Hungria, Deborah M Martínez-Baños, Christian R Peñafiel, et al.Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.European Urology Oncology|November 5, 2023
Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate CancerJohn K Lin, Caleb M Hearn, Emily Getzen, et al.Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.JAMA Network Open|January 18, 2022
Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care SystemKosj Yamoah, Kyung Min Lee, Shivanshu Awasthi, et al.Clinical Genitourinary Cancer|December 3, 2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityElizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patientsTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.BJU International|November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaGregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.Pageof 14